Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the BeShape One Device for Non-invasive Waist Circumference Reduction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female and male subjects ≥18 and ≤65 years of age.~2. Abdominal fat thickness of at least 1.5 cm (measured by calibrated caliper).~3. 18.5 ≤ BMI ≤ 33~4. Women of childbearing potential (i.e., not post-menopausal or surgically sterilize) must have a negative urine pregnancy test. Participating women of childbearing potential must be using a medically acceptable form of birth control for at least 3 months prior to enrollment.~5. Understand the study and volunteer to sign the informed consent.~6. Willing to follow the treatment and follow up schedule and post-treatment care instructions.~7. Willing to refrain from a change in diet, exercise or medication regimen for the duration of the study.~8. Willing to have de-identified images of the treated areas taken for possible use in publications and presentations.~Exclusion Criteria:~1. Pregnant women, intending to become pregnant during the study, less than 12 months after delivery, breastfeeding, or less than 6 weeks after completing breastfeeding;~2. Participation in another clinical study of another investigational device or drug involving the same anatomical site within the last 3 months, or, if it does not involve the same anatomical site, at the discretion of the researcher.~3. Subjects with significant systemic disease, such as ongoing hyperlipidemia, diabetes mellitus, hepatitis or other liver disease, HIV-positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease, and malignant neoplasms; undergoing chronic steroid or immunosuppressive therapy.~4. Subject having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.~5. An implanted pacemaker or any other implantable active device anywhere in the body.~6. Subjects with thyroid disease and / or metabolic syndrome.~7. Unstable weight within the last 6 months (i.e. + 3% weight change in the past six months).~8. Local skin pathologies or natural structure loss in the treated area (hernia) and / or loss of sensation or dysesthesia in the treated area.~9. Previous body contouring procedures in the treatment area within the past 12 months.~10. History of abdominal surgery, including laparoscopic procedures.~11. Caesarean section within 12 months.~12. Any permanent or temporary implant in the treatment area such as metal plates or an injected chemical substance such as silicone.~13. Actively expressed psychiatric or psychological state.~14. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months.~15. Any condition that, at the researcher's discretion, renders the subject unsuitable for participation in a clinical research study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- BeShape One Device Treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete